Redhill BEKINDA Day April 2017

April 27, 2017

Please join RedHill Biopharma for a Research & Development Day in New York City on April 27th.

Management to discuss BEKINDA (RHB-102) for Acute Gastroenteritis (Phase III) and IBS-D (Phase II).

Expert Guest Speakers to Include:

Robert A. Silverman, MD, MS
Lead Investigator, BEKINDA® Phase III Study
Emergency Medicine Specialist at the Hofstra North Shore-LIJ Medical Center, Associate Professor at the Hofstra Shore-LIJ School of Medicine in NY

Scott Harris, MD, MS, FACP, AGAF
Consultant to Redhill Biopharma
Center for Diagnostics and Therapeutics of the American Gastroenterological Assocation, Professor of Clinical Pharmacology and Physiology at Georgetown University School

Jerry Rosenblatt, PhD
Redhill Biopharma Advisory Board
Managing Director, Foster Rosenblatt

For more information or to RSVP please contact Kelly Mueller (

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

RedHill Biopharma [RDHL] US$169 MM MCap
Three com­pounds in Ph3 de­vel­op­ment, RHB-105 for H.Py­lori, RHB-104 for Crohn’s and BEKIN­DA for gas­troen­teri­tis and gas­tri­tis. Ad­di­tio­n­al as­sets in­clude YE­LI­VA, a SK2 se­lec­tive in­hibi­tor with a... [more in­for­ma­tion]

Participating Solebury Trout Representatives

Kelly Mueller
Solebury Trout